posted
Ingen Begins Manufacturing New Oxyview-Cannula for Sale in June 2009 Jun 2, 2009 9:15:00 AM 2009 GlobeNewswire, Inc.
YUCAIPA, Calif., June 2, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing aging population and emerging markets for Home (DME), Hospital and Aviation Industries, announced today that the company has started the manufacture of the new Oxyview-Cannula to be sold later this month.
There are a recorded 23 million patients in the U.S. using home oxygen therapy, and all of them, not including hospitalized patients, use several nasal cannulas each month. There are an estimated 600 million patients worldwide that require home oxygen therapy. The current market for the nasal cannula has a cost range of $2-$6 per cannula, and is used for approximately 10 days before disposed. These current cannulas do not include a built-in flow meter. The new disposable Oxyview-Cannula will include the nasal cannula and the Ingen Oxyview flow-meter attached at a cost of $4.75. Typically the nasal cannula is replaced 3-4 times each month because it builds up bacteria and moisture. The average list price for a nasal cannula is $5.75, however, the DME provider is responsible to include the cannula along with the other oxygen equipment reimbursable at a flat monthly rate from Medicare. There are several advantages to use the new Oxyview-Cannula, inclusive of allowing the patient to be assured that they are receiving the prescribed dosage of oxygen where it is need the most and troubleshooting equipment problems over the phone with the oxygen supplier preventing an on-site service call. Without the Oxyview-Cannula, patients cannot confirm oxygen flow nearest to them, nor can they actually be assured that the equipment is functioning properly. "The new Oxyview-Cannula should improve home oxygen therapy and decrease costs associated to unnecessary service calls," stated Chris Wirth, COO of Ingen Technologies.
The nasal cannula (NC) is a device used to deliver supplemental oxygen to a patient or person in need of extra oxygen. This device consists of a plastic tube which fits behind the ears, and a set of two prongs which are placed in the nostrils. Oxygen flows from these prongs. The nasal cannula is connected to an oxygen tank, a portable oxygen generator, or a wall connection in a hospital via a flow meter. The nasal cannula carries 1-6 liters of oxygen per minute. There are also infant or neonatal nasal cannulas which carry less than one liter per minute; these also have smaller prongs. The oxygen fraction provided to the patient ranges roughly from 24% to 35%. The nasal cannula was invented by Wilfred Jones and patented in 1949 by his employer, BOC.
The company has been selling Oxyview as an individually packaged respiratory product, and has now developed a disposable and more affordable Oxyview flow meter that will be attached and prepackaged to a variety of nasal cannula products. The company will sell the new Oxyview-Cannula under the Ingen logo. The potential market size for the new Oxyview-Cannula is approximately $200M per year in the US and $150M per year outside the US.
"The new disposable Oxyview-Cannula should revolutionize the home oxygen therapy market worldwide. There is nothing else in comparison, and Ingen will sell the new nasal cannula at competitive prices starting this month," stated Scott Sand, CEO and Chairman of Ingen Technologies.
About Oxyview:
Oxyview is a proprietary medical device with US-issued patents that stands alone in an increasing patient home oxygen therapy market while there are 23 million patients diagnosed with chronic obstructive pulmonary disease (COPD) in the United States, according to the World Health Organization, and another 12 million patients that are undiagnosed in the US. COPD is the fifth leading cause of death in the US and there are 600 million COPD patients worldwide where in most cases, COPD is either the first or second leading cause of death in other countries. The majority of COPD patients require continued home oxygen therapy, which includes all of the required equipment supplied by the home (DME) provider. With the new regulations for oxygen reimbursement in the US, the home (DME) providers need to cut costs to stay in business. Oxyview provides a substantial savings as a result of decreasing the number of service calls for the home (DME) provider. Oxyview is a pneumatic metering device that displays oxygen flow near the patient. The Oxyview flow meter easily and quickly installs on to the oxygen tubing nearest the patient where oxygen flow matters the most. Without the Oxyview, patients cannot confirm oxygen flow, and as a result there is an increase in anxiety and the patient calls the home (DME) provider with concerns. Oxyview also allows the home (DME) provider to troubleshoot other equipment problems over the telephone which eliminates an on-site visit with the patient. More important, the Oxyview provides the patient with more assurance that they are receiving adequate and prescribed oxygen flow. The Oxyview costs less than a single service call.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
CONTACT: Ingen Technologies, Inc. Chris Wirth 909-790-7180 info*ingen-tech.com www.INGEN-TECH.com
-------------------- " Cash is King " Posts: 1102 | From: NJ | Registered: Mar 2006
| IP: Logged |
posted
Ingen Pays Down Debt to Increase Shareholder Value
Jun 5, 2009 4:15:00 PM 2009 GlobeNewswire, Inc.
YUCAIPA, Calif., June 5, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing aging population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the company has paid off approximately 30% of its debt over the past 60 days with plans to pay-off all debt by the end of this first quarter.
Ingen had accumulated debt during 2008 due to the economy pressures in the United State and costs associated in the marketing and sale of their new Oxyview respiratory product. During the company's fourth quarter (March-May 31, 2009) the company paid off more than $200,000 in debt to creditors and vendors. "Ingen should be debt-free from all creditors and vendors before the end of our first quarter in August-2009," stated Thomas J. Neavitt, Chief Financial Officer.
The company management has implemented an aggressive program to reduce debt 100% by the end of August-2009, and commence deliveries of the new Oxyview-Cannula in June 2009. "This program improves shareholder value and provides a sound basis to launch our new respiratory products," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
About Oxyview:
Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
CONTACT: Ingen Technologies, Inc. Chris Wirth 909-790-7180 info*ingen-tech.com www.INGEN-TECH.COM
-------------------- " Cash is King " Posts: 1102 | From: NJ | Registered: Mar 2006
| IP: Logged |
posted
This has been pumped incessantly on Hot Stock e-Newsletter.
I bought one of their other picks last week - nxpn - at .30, went to .35. Now .18 (got as low as .15). Of course I didn't sell and I'm stuck with it. If you play these - you almost need to sit glued to your screen. Good Luck
Posts: 2793 | From: Coral Springs, FL, USA | Registered: Aug 2003
| IP: Logged |
posted
At .01 .... up 185.7% , already surpassing the 10-day volume average. Another big pick by O T C R E P O R T E R . C O M , they are on FIRE !! .... imho
-------------------- " Cash is King " Posts: 1102 | From: NJ | Registered: Mar 2006
| IP: Logged |
posted
CONGRATS to you guys that are in this one! I've got a couple of pinkies too many on my plate - so I didn't get in this one. Of course my INAR has nice news today - but didn't move THAT much; and CPSZ has GREAT news yesterday and went DOWN/stayed even! Geeez - Glad at least some people made money.
I've been out all morning - I see this sicker hit .02 ! WOW - almost 1 10 bagger in 24 hours - reminds me of UVCL and NEOM a few years back. A word to the wize - now that i's had it's run - you may want to get out today - or at LEAST get your principal and some profit out..... These USUALLY drop like a rock after they've been pumped so much and the paid touts have dumped, jmho - for what it's worth! Wish I hade been in this one with you all instead of what I'm stuck with!
Posts: 2793 | From: Coral Springs, FL, USA | Registered: Aug 2003
| IP: Logged |
posted
Nice movement for sure. Bought 150k shares at 0.0065, then another 50k shares when it colapsed down to 0.0105. Anyone else do that (buy in at .01ish)? Smart or not? This seems likely (IMO) to get back to the .02 high it had once the end of day trading frenzy begins (or tomorrow, imo). I think it plumetted due to profit securing...
Posts: 406 | From: San Diego | Registered: Jun 2009
| IP: Logged |
posted
This was my very first trade. Had been doing a lot of reading about Ingen while waiting for my account to setup and my funds to be put in place and figured I'd give it a shot.
I got in at .0026 for 160k sold 50k about an hour ago to cover investment with a little profit (should of seen my face when my sell order kept getting rejected, I figured out my problem).
I'm torn with what to do, being that if what the pr releases are true this company could do well selling there product.
Not sure if I should sell tomorrow or hang on to it.
I know most people shoot for the short term gains just wonder if this could go somewhere.
This is way more fun than poker!!
Posts: 4 | Registered: Jun 2009
| IP: Logged |
quote:Originally posted by DocDiggler: This was my very first trade. Had been doing a lot of reading about Ingen while waiting for my account to setup and my funds to be put in place and figured I'd give it a shot.
I got in at .0026 for 160k sold 50k about an hour ago to cover investment with a little profit (should of seen my face when my sell order kept getting rejected, I figured out my problem).
I'm torn with what to do, being that if what the pr releases are true this company could do well selling there product.
Not sure if I should sell tomorrow or hang on to it.
I know most people shoot for the short term gains just wonder if this could go somewhere.
This is way more fun than poker!!
In my experience, the fact that it is a OTC says it all. If i was in your situation i would sell all but 20k, and hold them just in case the stock 'goes to the moon'! You will never regret taking big profits regards of which way the price goes;)
-------------------- 'The rewards for those that persevere, far exceed the pain that must proceed the victory!' Posts: 399 | From: leeds, england | Registered: Jul 2006
| IP: Logged |
posted
If you want to hold, but worry about losing, set a sell limit that you would be okay with taking. ie. possibly set it at 0.0115 or lower. Just a thought.
I'm in for the ride right now, I don't have to much in it.
Hoping for another ride tomorrow in the up direction.
posted
Ahh, thanks for the clarification I understand the buy limit just fine, the sell limit I perceived a little different. I've just been taking a lot of information in lately, my eyes are starting to bleed.
Posts: 4 | Registered: Jun 2009
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Wall Bang]](graemlins/wallbang.gif)
loosing in a possible dump. 
